Option chain shows key data for BioStem Technologies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for BioStem Technologies.

BioStem Technologies (OTC:BSEM) Stock, Option Chain

BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its proprietary approach, Local MicroEnvironment Activation, uses combinations of Small Molecules, Cytokines, and Growth Factors to activate the microenvironment within the body to create communication for repair in the tissue. The Company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AmnioWrap2.

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond 

Biotech

News

Health Care

General

BSEM

Florida-based BioStem Technologies, Inc. (OTCMKTS: BSEM) is a biotech company focused on developing and manufacturing structural-tissue allografts derived from perinatal tissues and intended for use as a protective covering for soft-tissue wounds. 

How BioStem Plans To Grow Its Perinatal Allografts In 2023 – And Beyond

BioStem Reveals Plans For New Products, Expanded Sales And Manufacturing Capabilities At Dawson James Small Cap Growth Conference

Jason Matuszewski, CEO and co-founder of BioStem Technologies, Inc. (OTCMKTS: BSEM), presented at last year’s Dawson James Small Cap Growth Conference in October.

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care  

Interview

Benzinga recently spoke to the CEO of BioStem Technologies, Inc. (OTCMKTS: BSEM) (“BioStem”), Jason Matuszewski, about his company’s mission and future. 

Benzinga Speaks To BioStem Technologies About How Its Technology Is Changing The World Of Wound Care

BIOSTEM TECHNOLOGIES NEW by BioStem Technologies, Inc.

BioStem Technologies Inc

Press Releases

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions

Earnings

BioStem Technologies Reports Record Third Quarter 2024 Revenue of $82.6 Million

BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global

BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts

BioStem Technologies CEO to Present at Biotech Showcase 2025

BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®

BioStem Technologies Announces Record Preliminary Fourth Quarter Net Revenue of $102.9 Million, with Full-Year 2024 Net Revenue Expected to Reach $301.8 Million

BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers

BioStem Technologies

Zacks Investment Research

Comments

BioStem Technologies

BioStem Technologies (BSEM) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga